Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 87 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2014', provides an overview of the Onychomycosis (Tinea Unguium)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Onychomycosis (Tinea Unguium) Overview 8
Therapeutics Development 9
Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9
Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis 10
Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 11
Onychomycosis (Tinea Unguium) - Therapeutics under Investigation by Universities/Institutes 13
Onychomycosis (Tinea Unguium) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Onychomycosis (Tinea Unguium) - Products under Development by Companies 18
Onychomycosis (Tinea Unguium) - Products under Investigation by Universities/Institutes 19
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 20
Actavis plc 20
Eisai Co., Ltd. 21
Nihon Nohyaku Co., Ltd. 22
Helix BioMedix, Inc. 23
Kaken Pharmaceutical Co., Ltd. 24
Nuvo Research Inc. 25
Mayne Pharma Group Limited 26
Evolva SA 27
Novabiotics Ltd 28
Anacor Pharmaceuticals, Inc. 29
Moberg Pharma AB 30
Viamet Pharmaceuticals, Inc. 31
NAL Pharmaceuticals Ltd. 32
Meiji Seika Pharma Co., Ltd. 33
Blueberry Therapeutics Ltd 34
Onychomycosis (Tinea Unguium) - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
efinaconazole - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
itraconazole - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
luliconazole - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
albaconazole - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NP-213 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
terbinafine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
VT-1161 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
itraconazole - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ME-1111 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
E-1224 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
AN-2718 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HB-1275 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
EV-086 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
silver dihydrogen citrate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Nu-2 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
terbinafine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BB-0305 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules for Fungal Infections - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ELS-160 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NAL-3216 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Onychomycosis (Tinea Unguium) - Recent Pipeline Updates 72
Onychomycosis (Tinea Unguium) - Dormant Projects 78
Onychomycosis (Tinea Unguium) - Discontinued Products 79
Onychomycosis (Tinea Unguium) - Product Development Milestones 80
Featured News & Press Releases 80
Jun 09, 2014: Valeant Pharmaceuticals Announces FDA Approval Of Jublia for the Treatment of Onychomycosis 80
Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 80
Oct 28, 2013: Valeant Pharmaceuticals Announces Settlement Agreement With Anacor 81
Oct 18, 2013: Valeant Pharmaceuticals Announces Award In Anacor Dispute 81
Oct 03, 2013: Valeant Pharmaceuticals Announces Approval Of Jublia For The Treatment Of Onychomycosis In Canada 81
Sep 10, 2013: TOPICA Presents Interim Safety and Mycologic Results from Its Phase 2b/3 Onychomycosis Trial of 10% Luliconazole Solution at the Interscience Conference on Antimicrobial Agents and Chemotherapy 82
Jun 12, 2013: Topica Pharma Completes Enrollment For Phase IIb/III Onychomycosis Trial Of 10% Luliconazole Solution 83
May 28, 2013: FDA Rejects NDA For Valeant Pharma's Efinaconazole As Treatment For Onychomycosis 84
May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015 85
May 02, 2013: Anacor Pharma Provides Update Regarding Arbitration With Valeant Pharma 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2014 9
Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Comparative Analysis by Unknown Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Onychomycosis (Tinea Unguium) - Pipeline by Actavis plc, H2 2014 20
Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H2 2014 21
Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H2 2014 22
Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H2 2014 23
Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2014 24
Onychomycosis (Tinea Unguium) - Pipeline by Nuvo Research Inc., H2 2014 25
Onychomycosis (Tinea Unguium) - Pipeline by Mayne Pharma Group Limited, H2 2014 26
Onychomycosis (Tinea Unguium) - Pipeline by Evolva SA, H2 2014 27
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H2 2014 28
Onychomycosis (Tinea Unguium) - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 29
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H2 2014 30
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H2 2014 31
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H2 2014 32
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2014 33
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H2 2014 34
Assessment by Monotherapy Products, H2 2014 35
Number of Products by Stage and Target, H2 2014 37
Number of Products by Stage and Mechanism of Action, H2 2014 39
Number of Products by Stage and Route of Administration, H2 2014 41
Number of Products by Stage and Molecule Type, H2 2014 43
Onychomycosis (Tinea Unguium) Therapeutics - Recent Pipeline Updates, H2 2014 72
Onychomycosis (Tinea Unguium) - Dormant Projects, H2 2014 78
Onychomycosis (Tinea Unguium) - Discontinued Products, H2 2014 79